Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.
2.

Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel.

Yaari R, Kaliner E, Grotto I, Katriel G, Moran-Gilad J, Sofer D, Mendelson E, Miller E, Huppert A; POG group, Anis E, Kopel E, Manor Y, Mor O, Shulman L, Singer R, Weil M.

BMC Med. 2016 Jun 23;14(1):95. doi: 10.1186/s12916-016-0637-z. Erratum in: BMC Med. 2016;14(1):120.

3.

Questions regarding the safety and duration of immunity following live yellow fever vaccination.

Amanna IJ, Slifka MK.

Expert Rev Vaccines. 2016 Dec;15(12):1519-1533. Epub 2016 Jun 20. Review.

4.

Immunization rates at the school entry in 2012.

Weigel M, Bruns R, Weitmann K, Hoffmann W.

Dtsch Arztebl Int. 2014 Nov 14;111(46):788-94. doi: 10.3238/arztebl.2014.0788.

5.

Molecular epidemiology and recombination of human enteroviruses from AFP surveillance in Yunnan, China from 2006 to 2010.

Tang J, Yoshida H, Ding Z, Tao Z, Zhang J, Tian B, Zhao Z, Zhang L.

Sci Rep. 2014 Aug 14;4:6058. doi: 10.1038/srep06058.

6.

Viral Aetiology of Acute Flaccid Paralysis Surveillance Cases, before and after Vaccine Policy Change from Oral Polio Vaccine to Inactivated Polio Vaccine.

Saraswathy Subramaniam TS, Apandi MA, Jahis R, Samsudin MS, Saat Z.

J Trop Med. 2014;2014:814908. doi: 10.1155/2014/814908. Epub 2014 Mar 19. Review.

7.

Inactivated polio vaccine: its proposed role in the final stages of polio eradication.

Davis R, Biellik R.

Pan Afr Med J. 2013 Mar 13;14:102. doi: 10.11604/pamj.2013.14.102.2580. Print 2013. No abstract available.

8.

Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response.

Thompson KM, Wallace GS, Tebbens RJ, Smith PJ, Barskey AE, Pallansch MA, Gallagher KM, Alexander JP, Armstrong GL, Cochi SL, Wassilak SG.

Public Health Rep. 2012 Jan-Feb;127(1):23-37.

9.

Retrospective characterization of a vaccine-derived poliovirus type 1 isolate from sewage in Greece.

Dedepsidis E, Kyriakopoulou Z, Pliaka V, Kottaridi C, Bolanaki E, Levidiotou-Stefanou S, Komiotis D, Markoulatos P.

Appl Environ Microbiol. 2007 Nov;73(21):6697-704. Epub 2007 Sep 7.

10.

Shedding and reversion of oral polio vaccine type 3 in Mexican vaccinees: comparison of mutant analysis by PCR and enzyme cleavage to a real-time PCR assay.

Gnanashanmugam D, Falkovitz-Halpern MS, Dodge A, Fang M, Wong LJ, Esparza M, Hammon R, Rivas-Merelles EE, Santos JI, Maldonado Y.

J Clin Microbiol. 2007 Aug;45(8):2419-25. Epub 2007 Jun 20.

11.

Active immunization in the United States: developments over the past decade.

Dennehy PH.

Clin Microbiol Rev. 2001 Oct;14(4):872-908, table of contents. Review.

12.

Natural genetic exchanges between vaccine and wild poliovirus strains in humans.

Guillot S, Caro V, Cuervo N, Korotkova E, Combiescu M, Persu A, Aubert-Combiescu A, Delpeyroux F, Crainic R.

J Virol. 2000 Sep;74(18):8434-43.

13.

Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient.

Kew OM, Sutter RW, Nottay BK, McDonough MJ, Prevots DR, Quick L, Pallansch MA.

J Clin Microbiol. 1998 Oct;36(10):2893-9.

14.

Poliomyelitis: present epidemiological situation and vaccination problems.

Mensi C, Pregliasco F.

Clin Diagn Lab Immunol. 1998 May;5(3):278-80. Review. No abstract available.

Supplemental Content

Support Center